Cargando…
Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis
Biomarker research across the health-to-disease continuum is being increasingly applied. We applied blood-based metabolomics in order to identify patient clusters with a first demyelinating episode, and explored the prognostic potential of the method by thoroughly characterizing each cluster in term...
Autores principales: | Boziki, Marina, Pechlivanis, Alexandros, Virgiliou, Christina, Bakirtzis, Christos, Sintila, Styliani Aggeliki, Karafoulidou, Eleni, Kesidou, Evangelia, Theotokis, Paschalis, Nikolaidis, Ioannis, Theodoridis, Georgios, Gika, Helen, Grigoriadis, Nikolaos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735785/ https://www.ncbi.nlm.nih.gov/pubmed/36498904 http://dx.doi.org/10.3390/ijms232314578 |
Ejemplares similares
-
Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response
por: Boziki, Marina, et al.
Publicado: (2022) -
Secondary Central Nervous System Demyelinating Disorders in the Elderly: A Narrative Review
por: Bakirtzis, Christos, et al.
Publicado: (2023) -
CNS Ageing in Health and Neurodegenerative Disorders
por: Kesidou, Evangelia, et al.
Publicado: (2023) -
The Role of Diet and Interventions on Multiple Sclerosis: A Review
por: Stoiloudis, Panagiotis, et al.
Publicado: (2022) -
Biomarkers in Rare Demyelinating Disease of the Central Nervous System
por: Boziki, Marina, et al.
Publicado: (2020)